Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Download PDF Copy

Reviewed

Nov 28 2012Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

MM-302 is a nanotherapeutic encapsulation of doxorubicin with anti-HER2 antibody fragments attached to its surface. MM-302 specifically targets cancer cells that overexpress the ErbB2 (HER2) receptor, releasing doxorubicin within the cell and limiting uptake into normal cells.

"Merrimack believes MM-302 has the potential to achieve better efficacy than current standards of care and lessened risk of cardiac toxicity relative to free doxorubicin," said Ulrik B. Nielsen, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "We look forward to presenting both MM-302 Phase I data and preclinical research on its accompanying PET/CT imaging agent, MM-DX-929 at the upcoming Symposium."

Poster Overview:

A Phase 1 Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-positive (HER2+) Breast Cancer (Abstract #: P5-18-09)
- Poster Session 5: Treatment - HER2-Targeted Therapy
  - Friday, December 7, 2012
  - 5:00 - 7:00 p.m. CT, Exhibit Hall A-B
A Novel 64Cu-Liposomal PET Agent (MM-DX-929) Predicts Response to Liposomal Chemotherapeutics in Preclinical Breast Cancer Models (Abstract #: P4-02-05)
- Poster Session 4: Detection/Diagnosis - Molecular, Functional and Novel Imaging
  - Friday, December 7, 2012
  - 7:00 - 9:00 a.m. CT, Exhibit Hall A-B
Quantification of HER2 Expression at the Single Cell Level and HER2 Intratumoral Heterogeneity of Breast Cancer Tissue Samples Using Automated Image Analysis (Abstract #: P1-07-03)
- Poster Session 1: Prognostic and Predictive Factors – Biomarkers, Methods
  - Wednesday, December 5, 2012
  - 5:00 – 7:00 p.m. CT, Exhibit Hall A-B